Shanghai MicroPort Endovascular MedTech Co., Ltd’s (SHA: 688016) Cratos branched aortic stent graft system has received marketing approval from China’s National Medical Products Administration (NMPA). The approval is for the minimally invasive interventional treatment of thoracic aortic dissection involving branches of the aortic arch.
Product Innovation
The Cratos system represents an updated version of the company’s previously approved Castor branch stent, which became the world’s first approved branch aortic stent graft when it received marketing approval in China in 2017. The new iteration builds on this success with an optimized delivery system, integrated branch structure, and proximal segment free design.
Global Market Expansion
Since its initial approval, the Castor branch stent has gained marketing approval in the European Union, Latin America, and Southeast Asia. The updated Cratos system is poised to further expand the company’s presence in global markets, offering enhanced features and improved surgical options for thoracic aortic dissection.
Leave a Reply